Rafael (RFL) Stock Price, News & Analysis

Company Overview

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Key Stats

• Today's Range: $1.35 to $1.40
• 50-Day Range: $1.21 to $1.39
• 52-Week Range: $1.12 to $3.19
• Volume: 64,042 shs
• Average Volume: 50,683 shs
• Market Capitalization: $71.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Rafael Stock Analysis - MarketRank™

Rafael scored higher than 5% of companies evaluated by MarketBeat, and ranked 866th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Rafael has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Rafael has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Rafael has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of Rafael has been sold short.

Short Interest Ratio / Days to Cover

Rafael has a short interest ratio ("days to cover") of 0.66, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rafael has recently increased by 23.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rafael does not currently pay a dividend.

Dividend Growth

Rafael does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 2 people have added Rafael to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rafael insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.90% of the stock of Rafael is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.30% of the stock of Rafael is held by institutions.

Company Calendar

• Last Earnings: 3/16/2026
• Today: 6/02/2026
• Next Earnings (Estimated): 6/10/2026
• Fiscal Year End: 7/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Real Estate
• Current Symbol: NYSE:RFL
• CIK: 1713863
• Web: www.rafaelholdings.com
• Phone: (212) 658-1450
• Fax: N/A
• Employees: 20
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.52 million
• Net Margins: -2,846.60%
• Pretax Margin: -2,988.48%
• Return on Equity: -37.27%
• Return on Assets: -31.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.44
• Quick Ratio: 3.41

Sales & Book Value

• Annual Sales: $920 thousand
• Price / Sales: 77.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.91 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 52,010,000
• Free Float: 34,900,000
• Market Cap: $71.25 million
• Optionable: Optionable
• Beta: 0.54